Interpace Biosciences — Third Quarter 2026 Earnings Summary

Financial Performance

• Preliminary, unaudited revenue for the third quarter ended September 30, 2026, is expected to range from $10.1 million to $10.4 million.
• Expected quarter-over-quarter growth of approximately 11% to 14% compared to Q2 2026 revenue of $9.1 million.
• Expected year-over-year growth of approximately 15% to 18% compared to Q3 2025 revenue of $8.8 million.
• No specific data on earnings, profit margins, cash flow, deferred revenue, or debt is provided in this release.

Guidance and Future Outlook

• The company expects to report complete financial results for the third quarter of 2026 at a later date.
• The preliminary revenue range is based on information currently available to management and remains subject to completion of quarter-end closing procedures and review by the independent registered public accounting firm.
• Actual results may differ materially from the presented range.

Business Segments and Product Lines

• Interpace Biosciences is an emerging leader in personalized medicine through specialized molecular diagnostic tests.
• Commercialized thyroid tests include ThyGeNEXT® and ThyraMIR®v2, used together to support the evaluation of indeterminate thyroid nodules.

Other Key Points

• The issuer has filed a registration statement with the SEC for an offering to which this free writing prospectus relates.
• The preliminary, unaudited financial information has not been reviewed by the Company's independent registered public accounting firm.
• The expected revenues for Q3 2026 may not be indicative of the Company's net income for the period or full-year results.
• The Company undertakes no obligation to update forward-looking statements except as required by law.